GLP-1 medication level chart
A GLP-1 medication level chart shows how much of a weekly dose is estimated to stay in the body over time. Semaglutide has a half-life of about 7 days and tirzepatide about 5 days, per their FDA labels. On a steady weekly dose, the level rises for about 4 to 5 half-lives and then stays near the same range.
7 is weekly.
Up to 52.
The dose number to skip, for example 4 for the fourth dose.
An estimate from published half-life, not a blood level. Not for dosing decisions.
- Half-life
- 7 days
- From the FDA label
- Near steady state
- 28–35 days
- About 4 to 5 half-lives, or 4–5 weeks
- Steady-state peak
- 2× one dose
- About 2 mg-equivalent
- Week 12
- 50%
- Of the steady-state peak, just before the next dose
Not medical advice. This tool does math on the numbers you enter. It does not know your medication, your vial, or your health. Confirm every dose and draw with your prescriber or pharmacist.
Worked example
Take semaglutide at the same dose every 7 days. The half-life is about 7 days.
- After one week, half of the first dose is left. The second dose brings the level to 1.5 doses.
- After two weeks, the level is 0.75 before the third dose and 1.75 after it.
- Each week adds less. The peak gets close to 2 doses, and the low point before a dose gets close to 1 dose.
Tirzepatide has a shorter half-life of about 5 days. On a weekly dose, its peak gets close to about 1.6 doses, and it reaches that range a little sooner.
How the math works
The chart uses first-order decay. After each half-life, half of the medication is left. The amount left from one dose after t days is the dose × 0.5^(t ÷ half-life).
The chart adds up what is left from every earlier dose at each point in time. This is called superposition. The steady-state peak is one dose ÷ (1 − 0.5^(interval ÷ half-life)).
The model treats each dose as fully absorbed at the time of the shot. A real shot under the skin absorbs over one to three days, so real peaks come later and are lower. Treat the chart as a shape, not a measurement. It is an estimate from published half-life, not a blood level, and not for dosing decisions.
Frequently asked questions
The FDA label for semaglutide (Wegovy) gives an elimination half-life of about 1 week. The FDA label for tirzepatide (Zepbound) gives a half-life of about 5 days. Retatrutide is investigational. Its phase 2 trial reported a half-life of about 6 days.
A medication gets close to steady state after about 4 to 5 half-lives on the same dose. That is about 4 to 5 weeks for semaglutide and about 3 to 4 weeks for tirzepatide. Each dose increase starts that process again.
No. It is an estimate from the published half-life with a simple model. Absorption, body weight, and other factors change real levels from person to person. Do not use it to decide when or how much to take.
With a missed dose, the level keeps falling for a full extra interval before the next dose. On a long half-life, the drop is gradual. The labels give specific rules for a missed dose, so ask your prescriber or pharmacist what to do.
Each weekly dose adds to what is left from the earlier doses. Because the half-life is close to a week, part of each dose is still there when the next one goes in. The total rises until the amount that leaves each week equals one dose.
Do this math automatically in Vital
Vital estimates how much of your last logged dose is still in your system, from its half-life. It also reminds you when each dose is due.
Sources
- Wegovy® (semaglutide) prescribing information, section 12.3: elimination half-life of about 1 week · Novo Nordisk, FDA-approved label
- Zepbound® (tirzepatide) prescribing information, section 12.3: half-life of about 5 days · Eli Lilly and Company, FDA-approved label
- Jastreboff et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (half-life of about 6 days) · New England Journal of Medicine, 2023
Wegovy®, Ozempic®, and Rybelsus® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company.
Related guides
Tirzepatide Medication Level Chart: Half-Life, Steady State, and Missed Doses
A tirzepatide medication level chart and a semaglutide level chart built from label half-lives, with tables for one dose, the build-up to steady state, the weekly rise and fall, and a missed dose.
Peptide Half-Life: How Long Does It Stay in Your System
What peptide half-life means, how long semaglutide and tirzepatide stay in your system, the five half-lives rule, and why the BPC-157 half-life figure comes only from animals.
Missed a GLP-1 Dose? What Each Label Says
The missed-dose windows for Ozempic, Wegovy, Mounjaro, and Zepbound are not the same. Here is what each US label says, how to count the hours, and when to call your prescriber.
GLP-1 Dosing Schedules
How GLP-1 titration actually works. Why doses step up slowly, how long to plateau at each step, and what to do with missed doses.
Switching From Semaglutide to Tirzepatide: What to Know and Ask
Switching from semaglutide to tirzepatide is common, but the labels give no switching schedule. Here is what the head-to-head trial found, how clinicians approach the change, and the questions to ask before your first dose.
Side Effects After a Dose Increase: What Label Data Show
Why side effects after a dose increase are common on semaglutide and tirzepatide, what the labels say about GI events during titration, how long they tend to last, and when to call.